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Abstract
The disease burden due to  hepatitis  B  virus  (HBV)  infection  remains  significant;  350  million
people are infected world-wide, and around  half  a  million  deaths  each  year  are  due  to  HBV-
related liver disease and hepatocellular carcinoma (HCC).  Infant  immunisation  against  infection
was introduced in the early 1980s, the vaccine is routinely administered across regions  where  the
disease is endemic and has been shown to be safe and  effective.  However,  the  large  number  of
older individuals with persistent infection means that disease will not be reduced significantly  for
several decades. Furthermore, failure to respond to the vaccination has been observed in about 5%
of vaccinees and to date  we  have  limited  information  on  the  durability  of  vaccine  protection
against infection.
Hepatitis B infection and disease pathogenesis are known to be influenced by a number of  factors
including host genetics factors.  This  review  aims  to  give  an  overview  of  the  role  of  genetic
variation  in  persistent  HBV  infection  and  the  development  of  liver  disease  including  HCC.
Vaccine-induced immunity is,  at  least  in  part,  heritable  and  we  also  discuss  findings  on  the
genetic control of responses to HBV vaccination.
The epidemiology of HBV  infection  differs  by  world  region,  as  does  the  genetic  makeup  of
individuals originating from different  regions.  This  review  focuses  on  the  situation  in  Africa,
where hepatitis B is highly endemic.
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Introduction
Hepatitis  B  virus  infection  and  subsequent  disease  may   take   several   decades   to   develop.
Throughout the life course susceptibility to infection, disease progression and development of end
stage liver disease may all be modified by factors  such  as  the  viral  genotype,  age  at  infection,
mode of transmission, vaccine efficacy, reactivation / persistence, presence of other  infections  or
co-factors (e.g. aflatoxin, alcohol) and immune competence/suppression (Hall  et  al.,  2002).  Any
or all  of  these  may  be  affected  by  host  genetic  factors  but  the  role  of  these  is  still  poorly
understood. Yet, taking  a  genetic  approach  (in  conjunction  with  clinical  and  epidemiological
methods)  may  have  profound  implications  for  our   understanding   of   disease   pathogenesis,
molecular diagnosis, identification of novel treatments, and gene-environment interactions,  all  of
which may lead to better preventive strategies. In addition controlling for genetics may  allow  the
recognition of previously unknown environmental factors  leading  to  improved  prevention.  This
review  aims  to  summarise  our  current  understanding  of  the  role  of  host  genetic  factors   in
persistence of HBV infection, disease progression and vaccine-induced immunity.
Hepatitis B is highly endemic across many parts of Africa, Asia and in the Amazon basin of South
America; however the epidemiology of hepatitis B  virus  (HBV)  infection  differs  by  region,  as
does the genetic makeup of individuals originating from these  regions.  This  review  concentrates
mainly on the African context. Estimates by the World Health Organisation (WHO, 2008) and  the
Global Alliance for  Vaccines  and  Immunization  (GAVI,  2005)  show  that  around  two  billion
people, i.e. one-third of the global population, have been infected with HBV at some stage in their
lifetime. In Africa transmission occurs  in  early  life,  mainly  from  child-to-child  probably  by  a
variety of routes, relatively rarely from mother to child and in a second wave later in  life  through
sexual  contact.  Infection  at  birth  leads  to  persistent  (lifelong)   infection   in   about   90%   of
individuals, in childhood to about  25-40%,  but  infection  as  an  adult  results  in  less  than  10%
persistent infection.  This  infection  is  defined  by  the  presence  of  hepatitis  B  surface  antigen
(HBsAg) in blood and those affected have an up to 25% risk of dying prematurely  from  cirrhosis
(scarring of the liver) and/or  hepatocellular  carcinoma  (HCC),  although  the  risk  in  females  is
substantially lower than in males [pic](Bah et al., 2001; Dickinson et al., 2002; Yu et  al.,  2000a).
It is  thought  that  HBV  or  viral  proteins  may  play  a  role  in  HCC  induction,  that  prolonged
inflammation during infection accelerates hepatocarcinogenesis and that viral integration  into  the
hepatocyte genome is important (Hino, 2005).
The prevalence of persistent HBsAg carriage, as shown in Figure 1 (men only), and  consequently
HCC  varies  widely  even  within  the  African  continent  and   implies   higher   transmission   in
childhood in dry zones (Hall, 2004). In Africa HBV  infection  rates  equate  to  about  60  million
persistently infected people. Liver cancer - which is largely attributable to  HBV  –  is  among  the
most common cancers (11.5 and  5.0%  in  males  and  females,  respectively),  and  primary  liver
cancer accounts for an estimated 200,000 deaths in Sub-Saharan  Africa  every  year  [pic](Parkin,
2006; Parkin et al., 2008’).  However,  it  has  to  be  emphasised  that  we  are  still  lacking  good
prevalence and incidence data on many chronic diseases in Africa, including  HBV  infection  and
chronic liver disease.
It is clear that Hepatitis B remains one  of  the  major  diseases  of  mankind  and  poses  a  serious
global  health  burden,  especially  in  Sub-Saharan  Africa.  Treatment  of   HBV   infection   with
interferon-(, lamivudine, and more recent anti-virals is possible - but costly and thus generally  not
available in Africa.
However, HBV infection is preventable through vaccination, which has been available since 1982,
and immunization was recommended by the World Health Assembly in 1992 to be  introduced  in
all countries. Vaccination coverage across the African continent is variable, as shown in Figure  2.
Overall, large-scale vaccination has been  demonstrated  to  be  safe  and  cost-effective  given  the
high  level  of  vaccine   efficacy.   Vaccine-induced   immunity   is   affected   by   the   type   and
administration route of the vaccine itself, age, gender, UV light exposure, smoking,  co-infections,
and nutritional factors (reviewed by [pic](Van  Loveren  et  al.,  2001).  The  peak  anti-HBs  level
attained after vaccination can be used as a surrogate for  vaccine  efficacy  (i.e.  protection  against
infection and persistent carriage) long-term. Antibody decays in an exponential manner over  time
irrespective of the population under study (Jack et al., 1999; van der Sande et  al.,  2006)  although
protection appears to remain in many  who  have  lost  antibody.  Non-response  to  vaccination  is
observed in approximately 5% of vaccinees (Zuckerman, 2006).
This review describes genetic analysis approaches to  hepatitis  B  virus  persistence,  related  liver
cancer  and  vaccination  response  with  a  focus  on  studies  in  African  populations   (based   on
publications in  English  or  French).  Family  linkage  and  association  analysis  aim  to  map  the
chromosomal  location(s)  of  the  disease  causing  variant(s)  in  families  with  multiple  affected
individuals. Twin studies provide a means of distinguishing  the  risk  attributable  to  genetic  and
environmental  factors.  Population  based  (case-control)   association   studies   are   designed   to
determine if there is a correlation between an allelic variant and any  given  outcome,  e.g.  disease
status. Hepatitis B has been shown  to  cluster  in  families,  thus  it  has  been  possible  to  collect
evidence for a role of genetic factors in HBV infection, progression  and  vaccine  responses  from
family, twin and population based approaches.
Definitions
HBV infection  is  defined  by  the  presence  of  anti-core  antibodies  (anti-HBc).  IgM  anti-HBc
reflects recent infection and IgG anti-HBc  prior  or  active  infection.  Individuals  with  persistent
infection are in addition surface antigen (HBsAg)  positive.  HBV  DNA  is  usually  detectable  in
persistent carriers and  indicates  viral  replication  in  liver  cells.  The  presence  of  circulating  e
antigen (HBeAg) correlates with HBV DNA levels and therefore  also  indicates  viral  replication
with associated infectivity. Antibodies  to  surface  antigen  (anti-HBs)  appear  on  recovery  from
infection or are mounted in response to HBV vaccination. For further details see Decker  (Decker,
1998). Positivity for anti-core antibody in  the  absence  of  other  serological  markers,  “anti-HBc
alone” is compatible with either acute resolved infection or with persistent  HBV  infection  (Grob
et al., 2000).
Genetic susceptibility to persistent HBV infection
Family clustering of persistent HBV carriage has  been  observed  in  many  geographical  settings
[pic](Beasley et al., 1983; Blumberg et al.,  1969;  Bosch  et  al.,  1973;  Lin  et  al.,  2006;  Motta-
Castro et al., 2005; Obayashi et al., 1972; Stroffolini et al., 1991).  However,  there  appears  to  be
only one report of a family-based linkage study from The  Gambia  [pic](Frodsham  et  al.,  2006).
This study was  based  on  the  analysis  of  a  panel  of  over  300  microsatellite  markers  in  162
independent  affected  sibling  pairs  in  135  families  and   identified   a   region   of   linkage   on
chromosome 21q22 with a logarithm of odds (LOD) score of 3.16 (P<0.001). This region contains
the cluster of cytokine class II receptor (CRF2) genes, including IFNAR1, IFNAR2,  IL10RB  and
IFNGR2. The analysis of a further 22 mostly single  nucleotide  polymorphisms  (SNPs)  revealed
associations with persistent HBV infection (HBsAg + / anti-HBc-IgM -) of  two  non-synonymous
coding changes in IFNAR2 (F10V; rs1051393) and IL10RB (K47E; rs2834167), respectively, and
in vitro assays supported a functional effect of these variants in receptor signaling.
We found only one twin  study  regarding  susceptibility  to  HBV  infection  based  on  a  Chinese
population (Lin et al., 1989). Lin and co-investigators demonstrated differences in concordance of
infection in monozygotic (MZ) twins compared to controls and dizygotic (DZ) twins and  controls
(but no difference between MZ and DZ) as well as differences in carrier  status  between  MZ  and
DZ and MZ  and  controls  (but  not  DZ  and  controls),  suggesting  the  importance  of  maternal
infection in this population, and that  there  may  be  some  effect  of  host  genetic  factors  on  the
progression to persistent carrier status.
The bulk of work on genetic susceptibility to HBV infection comes from case-control  association
studies, with most of the earlier studies concentrating on variation in the major  histocompatibility
complex (MHC) located on chromosome 6. MHC  class  II  molecules  are  expressed  on  antigen
presenting cells and involved in presentation of pathogens such as HBV virus particles to T helper
cells,  thus  triggering  adaptive  immune  responses.  In  Gambian  children  and  adult  males  the
DRB1*1302 allele was shown to be associated with spontaneous elimination of infection (HBsAg
- / IgG anti-HBc +) (Thursz et al., 1995), and  this  finding  has  since  been  replicated  in  several
populations of Caucasian origin [pic](Hohler et al., 1997; Thio et  al.,  2003).  However,  this  was
not confirmed in a more recent study population from Togo and Benin, although sample  numbers
in  this  subgroup  analysis  were  very  low  [pic](Bronowicki  et  al.,  2008).  In  the  same   study
DRB1*08  was  correlated  with  persistent  infection  in  “HBc  alone”   subjects   and   DRB1*09
appeared associated with the presence of anti-HBs antibodies, a result that stands in contrast to the
findings from a Korean study (Ahn et  al.,  2000).  DQA1*0501  and  DQB1*0301,  but  not  other
human  leukocyte  antigen  (HLA)-A,  -B,  or  -DRB1  alleles,  were  associated  with   persistence
(HBsAg + / anti-HBc +) in African-Americans from the East coast of the USA (Thio et al., 1999).
The HLA-A, -B, and C antigen distribution  was  also  assessed  in  HBsAg  positive/negative  and
HBeAg positive/negative Senegalese individuals by Dieye and colleagues [pic](Dieye et al., 1999;
Obami-Itou et al., 2000). Associations between A1, A23, B8 and  Cw3  and  HBsAg  positivity  as
well as A1 and HBeAg positivity were found, suggesting an influence  on  persistence  as  well  as
infectivity. The findings relating to variation in the MHC region  suggest  that  further  studies  are
necessary to establish which specific alleles affect susceptibility to HBV persistence.
HLA studies based in non-African  populations  (e.g.  Europe,  Qatar,  China,  Korea,  USA)  have
been reviewed extensively [pic](de Andrade and de Andrade,  2004;  Frodsham,  2005;  He  et  al.,
2006; Thursz, 2001a; Thursz, 2001b; Wang, 2003). To date  one  genome-wide  association  study
(GWAS) has been published,  reporting  the  HLA-DPA1  and  HLA-DPB1  locus  to  be  robustly
associated with persistent HBV infection in Japanese and Thai [pic](Kamatani  et  al.,  2009).  The
authors  suggest  that  antigen  presentation  on  HLA-DP  molecules  might  be  critical  for  virus
elimination. The finding from this GWAS emphasizes the role of variation in MHC genes in HBV
disease progression.
Studies on non-MHC genes and susceptibility to and progression of HBV infection are limited,  in
particular with regard to those based in African populations or those of African origin; reports  are
available on: TNFA (tumour necrosis factor alpha), MBL2 (mannose binding  lectin,  also  known
as MBP), VDR (vitamin D receptor), CTLA4 (cytotoxic T-lymphocyte antigen 4), MTHFR (5,10-
methylenetetrahydrofolate        reductase),        MTR        (5-methyltetrahydrofolate-homocysteine
methyltransferase) [pic](Bronowicki et al., 2008) as well as IL10, IL19 and IL20 (Truelove  et  al.,
2008). Thursz et al. described that the -308 promoter  polymorphism  (rs1800629)  in  TNFA  was
associated with an approximately 2-fold increased risk  of  persistent  HBV  infection  (HBsAg  +,
total anti-HBc +, IgM anti-HBc -) in The Gambia (Thursz et al., 1996).  The  functional  relevance
of this variant remains unclear, but it is thought to affect TNF-(  expression  levels  and  may  thus
influence levels of this pro-inflammatory cytokine, which could have an impact  especially  at  the
early stages of infection. The  same  Gambian  population  (although  a  smaller  subset)  was  also
studied for variation in the MBL2 [pic](Bellamy et al., 1998). This protein is  important  in  innate
immunity due to its role in opsonisation and phagocytosis and due to the  presence  of  changes  in
the coding region  of  the  gene  that  affect  protein  serum  levels,  however,  no  association  was
reported  with  HBV  infection  or   persistence.   In   a   further   study   based   on   Gambians,   a
polymorphism in the VDR gene was genotyped  and  found  to  correlate  with  persistent  carriage
(HBsAg + / anti–HBc +) [pic](Bellamy et al., 1999). This is an intronic SNP (rs731236)  and  thus
not likely to be of functional relevance, although  the  VDR  has  been  shown  to  affect  immune-
regulatory processes and thus may be important in  viral  infection.  Finally,  the  screening  of  six
SNPs across the CTLA4 gene in African-Americans by Thio and colleagues revealed  single  SNP
and haplotype associations with infection and carriage (Thio et  al.,  2004).  In  particular  +49G/X
(rs231775)  was  detected  more  often  in  persons  who  recovered  from  infection   and   -6230A
(rs3087243)  more  frequent  in  individuals  with  viral  persistence.  CTLA4  is  a  protein  which
transmits  inhibitory  signals  to  T  cells  and  it  is  thought  to  be  crucial  in  immune  regulatory
processes.  Variation  in  determinants  of  homocysteine  metabolism,   which   may   affect   viral
inactivation  through  DNA  methylation  processes  and  thus  outcome  of  HBV  infection,   was
investigated in a population from Togo and Benin by  Bronowicki  and  colleagues  who  screened
markers in the MTHFR and MTR genes [pic](Bronowicki  et  al.,  2008).  SNPs  MTHFR  C677T
(rs1801133) and A1298C (rs1801131), as well as  MTR  A2756G  (rs1805087)  frequencies  were
compared between HBsAg positives and anti-HBs  positives  (all  anti-HBc  +).  The  presence  of
MTHFR 677T or MTR 2756G and Beninese origin was found to predict anti-HBs seroconversion.
The comparison between anti-HBs positive and all anti-HBs negative subjects (i.e. including  anti-
HBc negatives) only showed MTHFR  677T,  but  not  MTR  2756G,  and  Beninese  origin  to  be
correlated  with  presence  of  antibodies  to  surface  antigen.  Finally,  Truelove   and   colleagues
assessed 25 SNPs in IL10, 10 in IL19  and  7  in  IL20  in  a  case-control  cohort  of  398  African
Americans (and European Americans) with persistent or self-limiting HBV infection, matched  by
HIV status (Truelove et al., 2008). Two markers in  the  IL10  promoter  (including  rs1800896  at
position -1082) and an intergenic SNP near IL20 were associated with  persistent  HBV  infection,
whilst an intronic IL10 SNP and another intergenic SNP near IL20 correlated with viral clearance;
an IL20 haplotype was also associated with susceptibility to  persistent  infection  (for  details  see
table 1). IL19 and IL20 both  belong  to  the  IL10  family  of  genes  (which  are  known  immune
regulatory molecules), and are thought to share receptor chains between each other and with IL10,
thus potentially also sharing signalling pathways. The results presented by Truelove  et  al  do  not
point towards a functional marker in IL10 or IL20 and further fine-mapping  would  be  needed  to
identify any causative variant. It seems that none of these reports on non-MHC gene variation  has
been followed-up in other populations of African origin to date.
Reports in populations not of African origin have been published mostly on  genes  that  modulate
or  control  the  immune  response  to  HBV  infection.  Several  reviews  have  summarized  these
[pic](de Andrade and de Andrade, 2004; Frodsham, 2005; He et al., 2006; Sun et al., 2009; Wang,
2003), and include: TNF, CCR5, CTLA4, RANTES, MCP1, ESR1, IL10, IL18, IL19, IL20,  KIR,
FAS  and  it’s  ligand,  TBX21,  CD14,  CCR5,  VDR,  MBL2,  IFNG  and  receptors,  IFNA   and
receptors etc. A recent meta-analysis found no association between HBV infection  status  and  the
TNFA rs1800629 SNP at position -308 (Qin et al., 2010) in Asians and Europeans; yet  an  earlier
meta-analysis  did  correlate  this  variant  with  persistent  HBV   infection   in   Asians,   but   not
Europeans (Zheng et al., 2010).
Genetic factors in HBV-related liver disease and HCC
Cases of HCC cluster in families (Yu et al., 2000b), probably reflecting the clustering of persistent
carriers (see above), given that HCC is etiologically associated with HBV in 80% of cases in  high
endemicity areas and that the majority of deaths in HBV carriers is due to HCC [pic](Dickinson et
al., 2002; Parkin, 2006; Yu et al., 2000a). There are a number  of  studies  that  have  assessed  the
host genetic component in the development of HBV-related HCC, most  of  these  relate  to  Asian
populations.
As far as we are aware there  is  no  genome-wide  family  based  linkage  study  for  HBV-related
HCC, however, there is  a  publication  which  presents  findings  from  linkage  and  family-based
association analyses for chromosome 4 in  Chinese  families  from  Taiwan,  reporting  suggestive
evidence of linkage to 4q22.3-28.1 [pic](Shih et al., 2006). Similarly, only  anecdotal  evidence  is
available regarding twins with Demir  et  al.  describing  an  identical  Turkish  twin  brother  pair,
diagnosed at the same time with HCC and both confirmed to be persistent HBV carriers (Demir et
al., 2002).
Candidate genes for studies on liver disease relate to genes that affect immune responses  to  HBV
infection; genes that metabolise hormones or xenobiotics, genes that modulate the development of
fibrosis/cirrhosis,  and  genes  thought  to  affect  cancer  molecular  pathogenesis  such   as   those
controlling cell cycle control mechanisms,  DNA  repair,  cellular  motility,  cancer  predisposition
[pic](Furberg  and  Ambrosone,  2001;  Kim  and  Lee,  2005).  There  are  also  studies  that  have
examined genotypes of enzymes thought to activate aflatoxin to the reactive epoxide form. This is
important as there is  a  strong  interaction  between  aflatoxin  and  hepatitis  B  in  carcinogenesis
[pic](Sylla et al.,  1999;  Uwaifo  and  Bababunmi,  1984).  In  the  African  context  we  identified
several publications on genetics of HBV-related liver  disease  relating  to  Gambians,  Ghanaians,
Sudanese  and  Moroccans,  respectively.  Polymorphisms  in  enzymes  involved  in   carcinogen-
metabolism (glutathione S-transferases encoded by  GSTM1,  GSTT1,  and  epoxide  hydrolase  1
encode  by  EPHX1  (also  known  as  HYL1  or  mEH)  and  DNA   repair   (X-ray   repair   cross
complementing protein encoded by XRCC1) were  investigated  in  a  hospital-based  case-control
study of HCC in The Gambia [pic](Kirk et al., 2005).  Carriers  of  a  GSTM1  deletion  and  those
heterozygous for a coding change in the XRCC1 gene (Arg399Gln, rs25487) where more likely to
suffer from HCC, and this effect was even more  prominent  in  individuals  exposed  to  aflatoxin.
The authors concluded that genetic modulation of carcinogen metabolism and DNA repair appears
to alter susceptibility to HCC and that these effects may be modified by environmental factors, i.e.
aflatoxin exposure. An earlier study in rural Gambians had shown  the  GSTM1  null  genotype  to
lead to increased aflatoxin-adduct levels in HBsAg negative, but not  HBsAg  positive  individuals
with HCC [pic](Wild et al.,  2000).  Dash  and  colleagues  investigated  the  role  of  host  genetic
variation  in  GSTM1,  GSTT1  and  EPHX1  with  regard  to  aflatoxin   exposure   (measured   as
aflatoxin albumin adduct level in blood) in Ghana (Dash  et  al.,  2007).  Employing  multivariable
analysis (adjusting for gender, genotypes, HBsAg status, and age) they found  female  gender  and
EPHX1  R139H  (rs2234922)  heterozygote  status  to  associate  with  increased  mean   aflatoxin
albumin adduct levels. This indicates that these individuals may be most susceptible to aflatoxin  /
HBV-related liver disease, although HCC is known to be less common in women [pic](Bah et  al.,
2001; Yu et al., 2000a). However, HCC was not a known outcome in this study  population  and  a
future follow-up study would be necessary to shed more light on these relationships  between  risk
genotypes, gender, aflatoxin exposure and HCC. A group in Sudan  also  reported  on  correlations
between peanut butter intake (i.e. aflatoxin exposure) and HCC  patients,  in  individuals  with  the
GSTM1 null genotype, however neither GSTT1 nor EPHX  appeared  to  modify  this  association
[pic](Omer et al., 2001; Tiemersma et al., 2001). Further studies will be  necessary  to  disentangle
the relationship between aflatoxin exposure, host genetic factors and HCC by looking  at  two-and
three-way relationships between these factors. Finally, manganese superoxide dismutase,  encoded
by the SOD2 gene, is involved in the destruction of radicals which are normally  produced  within
cells and which are toxic to biological systems. A non-synonymous  coding  change  (Val  to  Ala,
rs1799725) has been shown to have functional effects on these processes and was recently studied
in  HCC  patients  in  Morocco  (Ezzikouri  et  al.,  2008).  HCC  cases  were  more  likely   to   be
homozygous for the Ala allele compared to controls,  and  this  association  was  even  stronger  in
those with confirmed hepatitis C infection. HBV infection was also assessed and the proportion of
HBsAg positives was about four times higher in the  HCC  group,  however,  the  total  number  of
persistent carriers was only 19 and thus too small for a subgroup analysis. It would  be  interesting
to assess this SOD2 variant in a larger HBV-related HCC case-control study.
Host  genetic  studies  on  HBV-related  liver  disease  including  cirrhosis  and  HCC   have   been
published on extensively in Asian populations and to a lesser extent in those  of  European  origin,
covering  a  large  number  of  candidate  genes  including  (and  this  is  not  an   exhaustive   list):
CYP1A1, ERS1, FAS, GSTM1, GSTT1,  IL10,  IL1B,  IL1RN,  NAT2,  TGFB,  TFNA,  XRCC1,
hMLH1, XPD (reviewed by [pic](Chen et al., 2005; Kim and Lee, 2005; Kirk et al., 2006;  Sun  et
al.,  2009)).  Recently,  a  GWAS  has  been  conducted   in   Chinese,   identifying   a   region   on
chromosome 1p33.26 (KIF1B, UBE4B and PGD) as susceptibility locus  for  HCC  in  individuals
persistently infected with HBV [pic](Zhang et al., 2010). The meta-analysis by Qin et al on TNFA
polymorphisms (see above) concluded  that  the  -308  promoter  variant  is  associated  with  liver
cancer in Asians and Caucasians when patients were compared to healthy controls,  but  not  when
compared to HBV infection cases (Qin et al., 2010).  This  shows  that  although  there  is  a  large
body of evidence of host genetic  factors  in  HBV-related  liver  disease  derived  especially  from
Asian  studies,  there  is  a  distinct  lack  of  equivalent  studies  from   Africa,   despite   the   high
prevalence of disease in both these regions.
Genetics of immunity induced by HBV vaccination
Family and twin studies indicate that there is a significant heritable component  to  HBV  vaccine-
induced immunity both within Africa and across the rest of the world  (reviewed  by  (Kimman  et
al., 2007). Newport et al. demonstrated higher concordance in MZ compared to DZ  twins  in  The
Gambia, with heritability estimates ranging between 63-85% (Newport et al.,  2004).  The  authors
further estimated the contribution of HLA DRB1  variation  to  account  for  15%  (0-63%)  of  the
heritability and thus  suggested  that  genes  outside  this  locus  significantly  influenced  vaccine-
induced antibody levels. No other family-based or twin study appears to have been carried  out  on
samples from the African continent. Elsewhere, a twin study was conducted in German  vaccinees
and identified a haplotype based on variation in the promoter of the  IL10  gene  and  HLA  DRB1
alleles to correlate with response to HBV vaccination (Hohler et  al.,  2005).  A  follow-up  of  this
study suggested that differences in the T cell recognition of peptide/MHC  complexes  are  critical
in T cell responsiveness to HBsAg [pic](Kruger et al., 2005). A family based association approach
revealed that carriage of the HLA class III C4AQ0 allele lead to non-  or  slow  response  to  HBV
vaccination in Italian  subjects  (De  Silvestri  et  al.,  2001).  Work  by  investigators  in  the  USA
showed that with respect to non-response HLA  identical  siblings  were  concordant  whereas  the
majority of haplo- or non-identical  siblings  were  discordant,  they  also  presented  evidence  for
linkage with the MHC locus (LOD 6.3) in the families screened (Kruskall et al., 1992).
As with genetic susceptibility to HBV infection, most population based investigations on hepatitis
B vaccine responses have concentrated on  the  role  of  variation  within  the  MHC  region.  Such
studies in various populations have been reviewed in detail [pic](Kimman et al., 2007; Milich  and
Leroux-Roels, 2003). Briefly, it appears  that  alleles  associated  with  high/normal  response  are:
DRB1*01, DRB1*I1, DRB1*15, DQB1*0501, DPB1*0401  and  DRPB1*0402;  whereas  alleles
correlated  with  non-  or  poor  response  are:   DRB1*03,   DRB1*07,   DQB1*02,   DPB1*1101,
DRB1*14, and DRQB1*020. The only  HLA  population-based  study  in  individuals  of  African
origin (other  than  the  above  twin  study  in  Gambians)  is  that  by  Wang  and  colleagues  who
assessed vaccine-response  genetics  in  an  ethnically  mixed  US  population  comprising  a  large
proportion of African-Americans (Wang et al., 2004). Non-response to vaccination was  attributed
to  variants  HLA-Cw*03,  DRB1*07  and  DQB1*02,  whereas  response   was   associated   with
DRB1*15  and  DQB1*06  (all  results  adjusted  for  ethnicity  and  other  covariates).   Of   these
associations with DRB1*07 and DQB1*02 as well as DRB1*15 have been replicated (see  above),
but another previously replicated association with DRB1*03 and non-/poor response was not seen
in the US based study.
Only a handful of reports on non-MHC genes have been published with  respect  to  HBV-vaccine
induced immunity, these describe the screening  of  genes  including  Hp  (Louagie  et  al.,  1993),
GNB3 (Lindemann et al., 2002); IL2, IL4,  IL6,  IL10,  and  IL12B  (Wang  et  al.,  2004)  TNFA,
IL1B, IL2, IL2RA, IL4, IL4RA, IL10, IL12B, IL12RB1, IL12RB2, and IL13 [pic](Yucesoy et al.,
2009). None of these are based on  populations  of  native  African  origin.  Wang  and  colleagues
(Wang et al., 2004) studied a population of predominantly black African Americans  and  reported
on a haplotype consisting of three  IL4  SNPs  (-1098G/T,  rs2243248;  -590C/T,  rs2243250;  and
-33C/T, rs2070874) associated with good response to HBV vaccination, whereas those carrying  a
4bp deletion  in  the  IL12B  promoter  were  shown  to  be  non-responsive.  In  this  sample  HIV
infection was also correlated with non-response to vaccination. IL4 is important in the modulation
of B cell function, in particular immunoglobulin switching, and IL12B associates  with  IL23A  to
form the IL-23 interleukin,  an  heterodimeric  cytokine  which  functions  in  innate  and  adaptive
immunity. A possible implication of variation in these genes on HBV  vaccine-induced  immunity
is  therefore  plausible.  The  study  by  Yucesoy  et  al   [pic](Yucesoy   et   al.,   2009)   describes
associations of a TNFA and a IL12B SNP with  variations  in  median  anti-HBs  antibody  levels;
details given on the  ethnicity  of  their  study  population  is  limited  (84%  of  141  non-Hispanic
Whites), but a very small number of African Americans may have been included, thus we mention
it in this review. A larger study comprising over 700 SNPs across a total  of  133  candidate  genes
reported on associations in relation to immune responses in over 600 HBV infant  vaccinees  from
The Gambia [pic](Hennig et  al.,  2008;  Ryckman  et  al.,  2010).  This  showed  that  variation  in
IFNG, MAPK8, IL10RA, CD44, CD58,  CDC42,  IL19,  IL1R1,  and  to  a  lesser  extent  ITGAL
affect peak anti-HBs level and that odds  of  core-conversion  despite  vaccination  was  associated
with variation in CD163. Although these are plausible candidate molecules,  the  associated  SNPs
in these genes were all in non-coding regions and are thus unlikely to  be  of  functional  relevance
(although they  may  be  in  linkage  disequilibrium  with  functional  variants).  A  coding  change
(R719T, rs2230433) in the ITGAL gene was the exception; this appears to lead to a good  immune
response in those homozygote for the Threonine allele.  ITGAL  forms  a  subunit  of  lymphocyte
function-associated antigen-1 (LFA1), together with ITGB2, and plays a  central  role  in  immune
cell  interaction  by  binding  to  ICAMs  and  regulating   leukocyte-endothelial   cell   interaction,
cytotoxic T-cell mediated killing, and antibody dependent killing by granulocytes and  monocytes.
The largest study in this field to date is that by Davila et al (Davila et al., 2010), and  comprised  a
two-stage screen of just under 6000 SNPs in over 900 immune genes with regard to HBV  vaccine
failure following a two-dose immunisation schedule in 981 Indonesians. Non-response was shown
to be associated with SNPs in BTNL2, IL6ST,  KLRF1,  LY6H,  MBL2,  TGFB3,  HLAB,  HLA-
DRA,  HLA-DRQB1,  FOXP1,   LILRB4,   TGFB2,   TNFSF15,   C5,   CCL15,   with   the   most
convincing  evidence  for  MHC  genes  and  the  latter  six  genes  listed.  Unfortunately,  a  direct
comparison between these two last  mentioned  larger  studies  (with  respect  to  sample  size  and
number of variants genotyped) is not possible due to differences in population, number of  vaccine
doses, age  at  vaccination  and  most  importantly  the  timing  and  measurement  of  the  primary
outcome measure of vaccine-induced anti-HBs level. INFG and CD44  may  possibly  represent  a
common  thread  across  majority  of  genes  shown  to  affect   HBV   vaccine-induced   immunity
identified in both the Gambian and Indonesian study based on literature searches (Ryckman et  al.,
2010).
Conclusions
This  review   highlights   how   little   we   know   about   host   genetic   factors   in   hepatitis   B
infection/persistence,  HBV-related  liver  disease  including  HCC,  and   immunity   induced   by
hepatitis B vaccination. Genetic variation may affect these outcomes  separately  or  jointly,  given
that  there  are  likely  to  be  commonalities  in  the  immune  responses  to  natural  infection  and
vaccination and that immune modulation leading to persistent infection may directly  or  indirectly
affect the development of HBV-related liver disease. The  majority  of  studies  published  to  date
have assessed variation in the MHC region and there is some evidence that  MHC  class  II  alleles
are important, but  even  here  further  research  is  needed.  Data  on  non-MHC  genes  is  at  best
scattered. In  addition,  many  genetic  studies  discussed  in  this  review  are  hampered  by  small
sample sizes, the  limited  number  of  markers/genes  screened,  differences  in  study  design  and
analysis, and the fact that results have not been replicated in most instances. There  is  furthermore
a discrepancy between the  reasonably  high  and  very  small  number  of  reports  from  Asia  and
Africa, respectively. As mentioned above, although  hepatitis  B  is  highly  endemic  in  both,  the
epidemiology of hepatitis B is different in Asia and Africa, so  these  regions  should  be  assessed
separately and/or comparatively. Within Africa it is notable that the majority of studies carried out
to date are based on Gambians. This is likely because there has been a long-standing investment in
hepatitis B work in The  Gambia  including  the  Gambian  Hepatitis  Intervention  Study  and  the
presence of a cancer registry there [pic](Bah et al., 2001; Viviani et al., 2008).
Future research should comprise a variety of populations (especially within the African continent),
so as to account for genetic variation between populations, but also differences  in  covariates  and
environmental factors, particularly with respect to aflatoxin exposure. More  well-designed  large-
scale studies  with  long(er)  follow-up  times  are  needed,  although  intermediate  (non-invasive)
phenotypes, e.g. fibrosis stage measured by ultrasound as early  indicator  of  disease  progression,
could also be assessed. GWAS would be useful for the identification of novel  genes,  i.e.  helping
to generate and evaluate hypotheses of pathways and mechanisms underlying susceptibility to and
pathogenesis of HBV infection, as  well  as  responses  to  vaccination.  Antigen  presentation  and
recognition, the magnitude or kinetics of virus- or vaccine-induced antibody response, lymphocyte
proliferation, and long-term immune memory are all processes that  are  likely  to  be  affected  by
genetic variants, many of which are yet to be identified. Replication/transferability of linkage  and
association signals should also be followed up, e.g. a systematic screening of the MHC region  for
instance would be warranted for HBV infection and vaccination-related  phenotypes.  This  would
ideally  also  be  followed  by  work  looking  into  the  functional  relevance  of  genetic  variation
especially with respect to the MHC region and TNF.  We  are  hopeful  that  with  the  advance  of
cheaper and more rapid genotyping and analysis methods as well as  more  multi-disciplinary  and
collaborative approaches, there will be greater opportunities to study the  host  genetics  related  to
hepatitis B in the broadest sense and thereby ultimately to improve diagnosis, prognosis, treatment
and prevention strategies of HBV-related pathogenesis.
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Glossary
GAVI   Global Alliance for Vaccines and Immunization
HBV    hepatitis B virus
HCC    hepatocellular carcinoma
HLA    human leukocyte antigen
LOD    logarithm of odds
MHC   major histocompatibility complex
MZ / DZ          monozygotic / dizygotic twin
SNP     single nucleotide polymorphism
WHO   World Health Organisation
Table  1:           Summary  of  reports  on  genetic  factors  in  susceptibility   to   persistent   HBV
infection,  liver  disease  and  HBV  vaccine-induced  immunity  (as  direct  or  indirect
outcome measure)
|Outcome   |Locus / Gene investigated |Study population (N     |Main finding                                 |Reference   |
|          |(number of markers        |total)                  |                                             |            |
|          |genotyped)                |                        |                                             |            |
|          |                          |                        |                                             |            |
|Susceptibi|Genome-wide scan; Chr21q22|The Gambia, families    |IFNAR2 F10V (rs1051393) and IL10RB K47E      |[pic](Frodsh|
|lity to   |including IL10RB, IFNAR1, |(N=182 families with one|(rs2834167) associated with viral clearance  |am et al.,  |
|persistent|IFNAR2, IFNGR2 (22        |or more affected        |                                             |2006)       |
|HBV       |additional markers)       |siblings; 192 unaffected|                                             |            |
|infection |                          |siblings)               |                                             |            |
|          |HLA-DRB1                  |The Gambia, case-control|DRB1*1302 correlated with viral clearance    |(Thursz et  |
|          |                          |(N=403 children; 135    |                                             |al., 1995)  |
|          |                          |adult males)            |                                             |            |
|          |HLA-DRB1; MTHFR, MTR      |Togo (N=305) and Benin  |DRB1*08 correlated with persistent infection |[pic](Bronow|
|          |                          |(N=150), case-control   |in “HBc alone” subjects; DRB1*09 and minor   |icki et al.,|
|          |                          |                        |alleles of MTHFR C677T (rs1801133), and MTR  |2008)       |
|          |                          |                        |A2756G (rs1805087) associated with presence  |            |
|          |                          |                        |of anti-HBs antibodies                       |            |
|          |HLA-A, -B, and -C         |Senegal, case-control   |A1, A23, B8 and Cw3 associations with HBsAg  |[pic](Dieye |
|          |                          |(N=194)                 |positivity; A1 association with HBeAg        |et al.,     |
|          |                          |                        |positivity                                   |1999;       |
|          |                          |                        |                                             |Obami-Itou  |
|          |                          |                        |                                             |et al.,     |
|          |                          |                        |                                             |2000)       |
|          |HLA-A, -B, -DQA1, -DQB1,  |USA, case-control (N=190|DQA1*0501 and DQB1*0301 associated with      |(Thio et    |
|          |-DRB1                     |African-Americans)      |persistence                                  |al., 1999)  |
|          |IL10 (25 SNPs), IL19 (10  |USA, case-control (N=398|IL10 (rs1800893, rs1800896) and IL20         |(Truelove et|
|          |SNPs), IL20 (7 SNPs)      |African-Americans)      |(rs1518108) as well as IL20 5-SNP haplotype  |al., 2008)  |
|          |                          |                        |associated with persistence; IL10 (          |            |
|          |                          |                        |rs1518110) and IL20 (rs1400986) associated   |            |
|          |                          |                        |with viral clearance                         |            |
|          |TNFA (1SNP)               |Gambia, case-control    |−308G/A (rs1800629) associated with          |(Thursz et  |
|          |                          |(N=507)                 |persistence                                  |al., 1996)  |
|          |VDR (1SNP)                |Gambia, case-control    |TaqI SNP (rs731236) associated with          |[pic](Bellam|
|          |                          |(N=530)                 |resistance to infection                      |y et al.,   |
|          |                          |                        |                                             |1999)       |
|          |MBL2 [also known as MBP]  |Gambia, case-control    |No association with SNPs at codon 52         |[pic](Bellam|
|          |(3 SNPs)                  |(N=337)                 |(rs5030737), 54 (rs1800450) and 57           |y et al.,   |
|          |                          |                        |(rs1800451)                                  |1998)       |
|          |CTLA4 (6 SNPs)            |USA, case-control (N=527|-1722C/+49A (rs733618/rs231775) containing   |(Thio et    |
|          |                          |including 22%           |haplotype associated with viral clearance;   |al., 2004)  |
|          |                          |African-Americans)      |+6230A (rs3087243) containing haplotype      |            |
|          |                          |                        |correlated with persistence                  |            |
|          |                          |                        |                                             |            |
|Liver     |GSTM1 (deletion), GSTT1   |The Gambia, case-control|GSTM1 deletion and XRCC1 heterozygotes       |[pic](Kirk  |
|disease / |(deletion), EPHX1 (1 SNP),|(N=624)                 |(R399Q, rs25487) associated with HCC;        |et al.,     |
|HCC /     |XRCC1 (1 SNP)             |                        |aflatoxin-related combined high-risk genotype|2005)       |
|aflatoxin |                          |                        |GSTM1 null, EPHX1 H113Y (rs1051740), and     |            |
|albumin   |                          |                        |XRCC1 heterozygotes at increased risk of HCC |            |
|level     |                          |                        |                                             |            |
|          |GSTM1 (deletion), GSTT1   |Gambia, case-control    |Increased mean adduct levels in non-HBV      |[pic](Wild  |
|          |(deletion), GSTP1 (1 SNP),|(N=357)                 |infected with GSTM1 null genotype            |et al.,     |
|          |EPHX1 (1 SNP)             |                        |                                             |2000)       |
|          |GSTM1 (deletion), GSTT1   |Ghana (N=114)           |Female gender, HBV status (HBsAg positivity) |(Dash et    |
|          |(deletion), EPHX1 (2 SNPs)|                        |and EPHX1 R139H (rs2234922) heterozygosity   |al., 2007)  |
|          |                          |                        |associated with increased aflatoxin-albumin  |            |
|          |                          |                        |adducts (i.e. risk factor for HCC)           |            |
|          |GSTM1 (deletion), GSTT1   |Sudan , case-control    |Correlations between aflatoxin exposure and  |[pic](Omer  |
|          |(deletion), EPHX1 (2 SNPs)|(N=355)                 |HCC in individuals with the GSTM1 null       |et al.,     |
|          |                          |                        |genotype                                     |2001;       |
|          |                          |                        |                                             |Tiemersma et|
|          |                          |                        |                                             |al., 2001)  |
|          |SOD2 [also known as       |Morocco, case-control   |A16V (rs4880; previously rs1799725)          |(Ezzikouri  |
|          |Mn-SOD] (1 SNP)           |(N=318 including 19     |associated with HCC, increased risk in HCV   |et al.,     |
|          |                          |HbsAg positives and 111 |infecteds (Note: HBV infecteds not analysed  |2008)       |
|          |                          |anti-HCV positives)     |separately, but higher frequency of HCC in   |            |
|          |                          |                        |HBsAg +)                                     |            |
|          |                          |                        |                                             |            |
|HBV       |IL2, IL4, IL6, IL10,      |USA, case control       |HLA-Cw*03, DRB1*07, DQB1*02 (as well as      |(Wang et    |
|vaccine-in|IL12B, HLA-A, -B, -Cw,    |(including N=104        |related haplotypes) and IL12B allele 2 (4pb  |al., 2004)  |
|duced     |DRB1 DRQ1                 |African-Americans)      |deletion) associated with non-responder      |            |
|immunity  |                          |                        |phenotype;                                   |            |
|          |                          |                        |DRB1*15, DQB1*06 and IL4 TTC haplotype       |            |
|          |                          |                        |(rs2243248, rs2243250, rs2070874) associated |            |
|          |                          |                        |with response                                |            |
|          |HLA DRB1                  |Gambia, twins (N=174    |Heritability for anti-HBs 77% (63–85%);      |(Newport et |
|          |                          |pairs)                  |variation due to DRB1 locus 15% (0–63%)      |al., 2005)  |
|          |133 mostly non-HLA genes  |Gambia,                 |IFNG (rs2069727), CD58 (rs1414275,           |[pic](Hennig|
|          |(715 SNPs)                |cohort/case-control     |rs1016140), MAPK8 (rs3827680, rs10857565),   |et al.,     |
|          |                          |(N=662+393 as 2-stage   |IL10RA (rs2508450, rs2229113), CD44          |2008;       |
|          |                          |screen)                 |(rs353644, rs7937602), and ITGAL (R719V,     |Ryckman et  |
|          |                          |                        |rs4243232) and haplotypes in CD58            |al., 2010)  |
|          |                          |                        |(rs1414275-rs11588376-rs1016140), CD44       |            |
|          |                          |                        |(rs353644-rs353630-rs7937602), CDC42         |            |
|          |                          |                        |(rs2056974-rs2473316), IL19                  |            |
|          |                          |                        |(rs12409415-rs2056225-rs2243158), and IL1R1  |            |
|          |                          |                        |(rs2287047-rs997049-rs3917299) associated    |            |
|          |                          |                        |with peak anti-HBs level;                    |            |
|          |                          |                        |CD163 (rs6488340, rs4883263) correlated with |            |
|          |                          |                        |anti-HBc positivity despite vaccination      |            |
|          |                          |                        |                                             |            |
Note: References in this table are limited  to  studies  relating  to  African  or  African-American  populations,  reports
relating to other populations are summarised in the main text of this review.
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